91 related articles for article (PubMed ID: 23746320)
1. Words of wisdom. Re: androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
Schrader AJ; Schrader MG; Cronauer MV
Eur Urol; 2013 Jul; 64(1):169-70. PubMed ID: 23746320
[No Abstract] [Full Text] [Related]
2. Words of wisdom: re: androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
Luo J; Pienta KJ
Eur Urol; 2013 Aug; 64(2):339-40. PubMed ID: 23830228
[No Abstract] [Full Text] [Related]
3. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
Li Y; Chan SC; Brand LJ; Hwang TH; Silverstein KA; Dehm SM
Cancer Res; 2013 Jan; 73(2):483-9. PubMed ID: 23117885
[TBL] [Abstract][Full Text] [Related]
4. Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Anand AU; Bjartell A
Eur Urol; 2015 Feb; 67(2):349-50. PubMed ID: 25760252
[No Abstract] [Full Text] [Related]
5. Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Taneja SS
J Urol; 2015 Feb; 193(2):538. PubMed ID: 25617272
[No Abstract] [Full Text] [Related]
6. Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer.
Sun M; Abdollah F
Eur Urol; 2015 Jul; 68(1):162-3. PubMed ID: 26088731
[No Abstract] [Full Text] [Related]
7. Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants?
Sprenger C; Uo T; Plymate S
Ann Oncol; 2015 Sep; 26(9):1805-1807. PubMed ID: 26199394
[No Abstract] [Full Text] [Related]
8. Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer.
Sartor O; Dong Y
Asian J Androl; 2015; 17(3):439-40. PubMed ID: 25532583
[TBL] [Abstract][Full Text] [Related]
9. Words of wisdom. Re: Enzalutamide in metastatic prostate cancer before chemotherapy.
Althaus A; Kibel A
Eur Urol; 2015 Jan; 67(1):174. PubMed ID: 25528395
[No Abstract] [Full Text] [Related]
10. Estrogen-Mediated Activation of H875Y Androgen Receptor Mutation in a Prostate Cancer Patient.
Vasudevamurthy AK; Ledet E; Garvey C; Lewis BE; Sartor O
Clin Genitourin Cancer; 2017 Feb; 15(1):e111-e113. PubMed ID: 27527401
[No Abstract] [Full Text] [Related]
11. AR-V7 predicts prostate cancer treatment response.
Cancer Discov; 2014 Nov; 4(11):OF1. PubMed ID: 25367950
[No Abstract] [Full Text] [Related]
12. Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.
Bryce AH; Antonarakis ES
Int J Urol; 2016 Aug; 23(8):646-53. PubMed ID: 27255944
[TBL] [Abstract][Full Text] [Related]
13. Words of wisdom. Re: Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.
Beuzeboc P
Eur Urol; 2014 Dec; 66(6):1189-90. PubMed ID: 25587594
[No Abstract] [Full Text] [Related]
14. Are androgen receptor variants a substitute for the full-length receptor?
Lu J; Van der Steen T; Tindall DJ
Nat Rev Urol; 2015 Mar; 12(3):137-44. PubMed ID: 25666893
[TBL] [Abstract][Full Text] [Related]
15. Word of wisdom. Re: enzalutamide in metastatic prostate cancer before chemotherapy.
Chow K; Murphy DG
Eur Urol; 2014 Oct; 66(4):785-6. PubMed ID: 25218073
[No Abstract] [Full Text] [Related]
16. Resistance to androgen-pathway drugs in prostate cancer.
Steinestel J; Schrader AJ; Luedeke M
N Engl J Med; 2014 Dec; 371(23):2234. PubMed ID: 25470703
[No Abstract] [Full Text] [Related]
17. Resistance to androgen-pathway drugs in prostate cancer.
Ozaki Y; Miura Y; Takano T
N Engl J Med; 2014 Dec; 371(23):2233-4. PubMed ID: 25470702
[No Abstract] [Full Text] [Related]
18. Resistance to androgen-pathway drugs in prostate cancer.
Şendur MA; Akıncı MB; Yalçın B
N Engl J Med; 2014 Dec; 371(23):2233. PubMed ID: 25470701
[No Abstract] [Full Text] [Related]
19. Resistance to androgen-pathway drugs in prostate cancer.
Antonarakis ES; Nakazawa M; Luo J
N Engl J Med; 2014 Dec; 371(23):2234. PubMed ID: 25470700
[No Abstract] [Full Text] [Related]
20. [Androgen receptor variants in prostate cancer].
Schreyer E; Barthélémy P; Cottard F; Ould Madi-Berthélémy P; Schaff-Wendling F; Kurtz JE; Céraline J
Med Sci (Paris); 2017; 33(8-9):758-764. PubMed ID: 28945566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]